- Home
- ACRS
as 11-21-2024 4:00pm EST
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | WAYNE |
| Market Cap: | 132.0M | IPO Year: | 2015 |
| Target Price: | $7.20 | AVG Volume (30 days): | 6.0M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.77 - $5.17 | Next Earning Date: | 11-06-2024 |
| Revenue: | $27,079,000 | Revenue Growth: | 26.35% |
| Revenue Growth (this year): | -53.34% | Revenue Growth (next year): | -31.71% |
Latest Aclaris Therapeutics Inc. News
ACRS Breaking Stock News: Dive into ACRS Ticker-Specific Updates for Smart Investing
MT Newswires
16 hours ago
Cantor Fitzgerald Upgrades Aclaris Therapeutics to Overweight
TipRanks
2 days ago
Aclaris Therapeutics upgraded to Buy from Hold at Jefferies
TipRanks
2 days ago
Aclaris Therapeutics upgraded to Buy from Neutral at BTIG
Benzinga
2 days ago
Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments
MT Newswires
2 days ago
Aclaris Therapeutics Shares Soar After Multiple Analyst Upgrades
MT Newswires
2 days ago
Top Midday Gainers
Pharmaceutical Technology
3 days ago
Aclaris Therapeutics secures global rights to Biosion’s antibodies
Zacks
3 days ago
ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs
Compare ACRS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACRS Aclaris Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.